Total Payments
$445,519
2024 Payments
$1,543
Companies
29
Transactions
320
Medicare Patients
246
Medicare Billing
$43,012
Payment Breakdown by Category
Research$431,442 (96.8%)
Food & Beverage$7,388 (1.7%)
Other$3,500 (0.8%)
Travel$3,099 (0.7%)
Education$91.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $431,442 | 26 | 96.8% |
| Food and Beverage | $7,388 | 272 | 1.7% |
| Honoraria | $3,500 | 1 | 0.8% |
| Travel and Lodging | $3,099 | 10 | 0.7% |
| Education | $91.00 | 11 | 0.0% |
Payments by Type
Research
$431,442
26 transactions
General
$14,077
294 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Overseas Pharmaceuticals LLC | $367,879 | 2 | $0 (2023) |
| Eli Lilly and Company | $53,509 | 7 | $0 (2022) |
| SANOFI-AVENTIS U.S. LLC | $5,744 | 7 | $0 (2020) |
| HRA Pharma | $5,700 | 2 | $0 (2020) |
| SANOFI US SERVICES INC. | $2,323 | 14 | $0 (2018) |
| PFIZER INC. | $1,881 | 5 | $0 (2018) |
| Janssen Pharmaceuticals, Inc | $1,390 | 44 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $1,209 | 47 | $0 (2024) |
| Endo USA, Inc. | $1,142 | 10 | $0 (2024) |
| Amgen Inc. | $1,128 | 14 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,543 | 29 | Endo USA, Inc. ($1,142) |
| 2023 | $23,913 | 38 | Overseas Pharmaceuticals LLC ($23,145) |
| 2022 | $346,422 | 38 | Overseas Pharmaceuticals LLC ($344,734) |
| 2021 | $53,074 | 52 | Eli Lilly and Company ($51,813) |
| 2020 | $3,499 | 33 | HRA Pharma ($2,200) |
| 2019 | $10,109 | 49 | SANOFI-AVENTIS U.S. LLC ($5,569) |
| 2018 | $5,108 | 46 | SANOFI US SERVICES INC. ($2,323) |
| 2017 | $1,850 | 35 | Amgen Inc. ($889.42) |
All Payment Transactions
320 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $21.59 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/15/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $19.13 | General |
| Category: Diabetes | ||||||
| 10/01/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $13.43 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/27/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $18.91 | General |
| Category: Diabetes | ||||||
| 08/21/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $26.53 | General |
| Category: RESPIRATORY | ||||||
| 08/12/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $25.45 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 07/17/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $19.50 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/26/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug), SYNJARDY | Food and Beverage | In-kind items and services | $28.14 | General |
| Category: DIABETES | ||||||
| 06/25/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $15.31 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/18/2024 | Endo USA, Inc. | — | Food and Beverage | In-kind items and services | $75.00 | General |
| 06/18/2024 | Endo USA, Inc. | — | Food and Beverage | In-kind items and services | $46.00 | General |
| 06/18/2024 | Endo USA, Inc. | — | Food and Beverage | In-kind items and services | $45.00 | General |
| 06/18/2024 | Endo USA, Inc. | — | Food and Beverage | Cash or cash equivalent | $32.44 | General |
| 06/18/2024 | Endo USA, Inc. | — | Food and Beverage | In-kind items and services | $27.50 | General |
| 06/18/2024 | Endo USA, Inc. | — | Travel and Lodging | Cash or cash equivalent | $14.74 | General |
| 06/17/2024 | Endo USA, Inc. | — | Travel and Lodging | In-kind items and services | $681.95 | General |
| 06/17/2024 | Endo USA, Inc. | — | Travel and Lodging | In-kind items and services | $160.17 | General |
| 06/17/2024 | Endo USA, Inc. | — | Food and Beverage | Cash or cash equivalent | $44.05 | General |
| 06/17/2024 | Endo USA, Inc. | — | Travel and Lodging | Cash or cash equivalent | $14.74 | General |
| 06/11/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $17.88 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/22/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $18.16 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/22/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.34 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/15/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $20.80 | General |
| Category: Diabetes | ||||||
| 05/07/2024 | Lilly USA, LLC | JARDIANCE (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $30.12 | General |
| Category: Diabetes | ||||||
| 04/23/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug), TRADJENTA | Food and Beverage | In-kind items and services | $25.09 | General |
| Category: DIABETES | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double-Blind, Parallel-Arm Study Comparing the Efficacy of Investigational Product Ibuprofen Modified-Release Tablets 800 mg and Placebo in Patients with Chronic Pain Related to Osteoarthritis of the Knee. | Overseas Pharmaceuticals LLC | $367,879 | 2 |
| A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 | Eli Lilly and Company | $37,102 | 3 |
| PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 | Eli Lilly and Company | $16,407 | 4 |
| A 26-week Randomized, Open-label, Active-controlled, 2-treatment Arm, Parallel Group Multi-center Study, Comparing the Efficacy and Safety of Soliqua 100/33 Versus Lantus in Ethnically/Racially Divers | SANOFI-AVENTIS U.S. LLC | $5,531 | 2 |
| A 26-week Randomized, Open-label, Active-controlled, 2-treatment Arm, Parallel Group Multi-center Study, Comparing the Efficacy and Safety of Soliqua?100/33 Versus Lantus? in Ethnically/Racially Di | SANOFI US SERVICES INC. | $2,323 | 14 |
| Adherence with continuous-use oral | HRA Pharma | $2,200 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 77 | 147 | $20,250 | $11,635 |
| 2022 | 2 | 56 | 126 | $18,900 | $11,677 |
| 2021 | 3 | 73 | 139 | $19,350 | $12,706 |
| 2020 | 1 | 40 | 91 | $13,650 | $6,994 |
Total Patients
246
Total Services
503
Medicare Billing
$43,012
Procedure Codes
9
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 43 | 112 | $16,800 | $9,113 | 54.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 17 | 17 | $2,550 | $2,386 | 93.6% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 17 | 18 | $900.00 | $136.37 | 15.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 38 | 108 | $16,200 | $9,079 | 56.0% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 18 | 18 | $2,700 | $2,598 | 96.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 39 | 104 | $15,600 | $9,641 | 61.8% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 20 | 20 | $3,000 | $2,932 | 97.7% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 14 | 15 | $750.00 | $132.60 | 17.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 40 | 91 | $13,650 | $6,994 | 51.2% |
About Dr. Francisco Badar, MD
Dr. Francisco Badar, MD is a Family Medicine healthcare provider based in Cerritos, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/08/2008. The National Provider Identifier (NPI) number assigned to this provider is 1760667729.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Francisco Badar, MD has received a total of $445,519 in payments from pharmaceutical and medical device companies, with $1,543 received in 2024. These payments were reported across 320 transactions from 29 companies. The most common payment nature is "" ($431,442).
As a Medicare-enrolled provider, Badar has provided services to 246 Medicare beneficiaries, totaling 503 services with total Medicare billing of $43,012. Data is available for 4 years (2020–2023), covering 9 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Cerritos, CA
- Active Since 01/08/2008
- Last Updated 10/03/2023
- Taxonomy Code 207Q00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1760667729
Products in Payments
- ADLYXIN (Drug) $5,531
- Opill Norgestrel Tablets (Drug) $3,500
- SOLIQUA (Drug) $2,448
- Opill (Drug) $2,200
- PREVNAR - 13 (Biological) $1,683
- FARXIGA (Drug) $1,029
- Repatha (Biological) $870.06
- JARDIANCE (Drug) $835.73
- INVOKANA (Drug) $712.35
- XARELTO (Drug) $677.60
- Vascepa (Drug) $414.91
- Kerendia (Drug) $348.23
- Ozempic (Drug) $243.87
- Otezla (Drug) $215.99
- MOUNJARO (Drug) $212.07
- TRADJENTA (Drug) $197.54
- RYBELSUS (Drug) $174.87
- TRULICITY (Drug) $150.68
- VTAMA (Drug) $125.44
- BYDUREON (Drug) $124.91
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Cerritos
Dr. Emerico Csepanyi, M.d, M.D
Family Medicine — Payments: $152,332
Family Medicine $152,332
Yoon Pak, M.d, M.D
Family Medicine — Payments: $23,882
Family Medicine $23,882
Dr. John Kim, M.d, M.D
Family Medicine — Payments: $15,766
Family Medicine $15,766
Gina Rocillo, Md, MD
Family Medicine — Payments: $2,667
Family Medicine $2,667
Rosemarie Melchor, Md, MD
Family Medicine — Payments: $660.02
Family Medicine $660.02
Long Dang, M.d, M.D
Family Medicine — Payments: $528.38
Family Medicine $528.38